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ABSTRACT 
 
 
 
 
 
 
 
 
 
SYNTHESIS OF THE CONFORMATIONALLY CONTROLLED  
β-TURN MIMETIC TORSION BALANCE CORE SCAFFOLD 
Alyssa B. Lypson, M.S. 
University of Pittsburgh, 2018 
 
 
The molecular torsion balance concept was applied to a new conformationally 
controlled scaffold to accurately evaluate pairwise amino acid interactions in an antiparallel β-
sheet motif. The scaffold’s core design combines (ortho-tolyl)amide and o,o,o′-trisubstituted 
biphenyl structural units to provide a geometry better-suited for intramolecular hydrogen 
bonding. The aim of this study was to develop synthetic methods for the core scaffold and to 
conduct a preliminary investigation into the improved sequence alignment on upper and lower 
aromatic rings to promote hydrogen bond formation at the correct distance and antiparallel 
orientation. 
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1.0  INTRODUCTION 
1.1 INTRODUCTION TO THE TORSION BALANCE 
The concept of a “molecular torsion balance” was introduced in 1994 to describe a tool to 
examine molecular interactions present in biomolecules.1 Like a protein folding model, the torsion 
balance has two configurations.  These configurations represent the folded and unfolded states of 
a protein, and are distinguishable in the original example because of the presence of a gently 
restricted aryl-aryl bond rotation (∆G‡ = 14 kcal∙mol-1; Figure 1).1 The original molecular torsion 
balance featured an asymmetrical top half attached to the bottom half’s Trӧger’s base moiety. The 
flexibility of the dibenzodiazocine unit allows the needed self-adjustment of distances required to 
permit attractive non-covalent interactions. The barrier to interconversion separates the 
conformations into two distinct thermodynamic states with lifetimes that allow for a direct 
measurement of their ratio by 1H NMR spectroscopy. Intramolecular forces and solvent effects are 
identified by any deviation of the 1:1 ratio between the two states. The first generation torsion 
balance in Figure 1 has been utilized to investigate the benzene dimer edge-to-face, aryl- and alkyl-
CH-π interactions, and the hydrophobic effect.1 A second generation balance was later 
implemented to measure noncovalent interactions in water.2,3 
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Figure 1.  Folded (left) and unfolded (right) conformational states of the first-generation 
torsion balance. 
1.2 DESIGN OF THE CONFORMATIONALLY CONTROLLED TORSION 
BALANCE PERTINENT TO PEPTIDES 
Enzyme and drug-receptor binding rely upon many inter- and intramolecular interactions.  
Efforts have been made to design secondary protein mimetic structures, such as antiparallel β-
sheet mimics4 that accurately model protein folding.5-7 Gellman’s β-hairpin motif was developed 
to measure the folding and stability of β-sheets in water.  This study provided valuable NMR data 
to relate the thermodynamic parameters between two conformational states.5 Nowick and 
coworkers utilize the incorporation of natural and synthetic amino acids to generate a protein 
folded state of a β-sheet.6  Several other studies designed to probe structural aspects of β-motifs, 
reveal their flexibility by integrating peptidomimetics into β-hairpins and β-sheets.8  
A peptide torsion balance hybrid (Figure 2) was developed by the Wilcox group to 
investigate the pair-wise amino acid interactions in anti-parallel orientation of a β-sheet, as well 
as, short β-strand stability with changes in amino acids.9 In this case, the dibenzodiazocine torsion 
balance scaffold was not useful.  Modeling indicated that the scaffold did not have the correct 
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shape to (1) match the ends of an anti-parallel β-sheet and to (2) achieve the configuration required 
for intramolecular peptidomimetic hydrogen bond formation.   
The two-state nature of folding, as shown in Figure 2, was imposed by the restricted 
rotation around an aryl-nitrogen bond.10,11  This core structure was developed to mimic a β-turn, 
and thus allow us to acquire data for implementation in molecular recognition and protein folding 
models.   
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Figure 2.  Example of two conformations of the β-turn mimetic torsion balance.  The R 
groups are different and each represents an amino acid side chain. 
 
This design featured the substitution of an o,o,oʹ-trisubstituted biphenyl as our established 
torsion balance structural unit with an incorporated (ortho-tolyl)amide unit.  Thus, both the aryl-
aryl11 and N-aryl10 bonds are sites for bond restriction.  Although ortho-substituents are mostly 
responsible for the biaryl bond restriction, the incorporation of meta-substituents are also known 
to offer a rotational restriction due to a buttressing effect.11a,b  The ortho substituent is well-known 
to constrain rotation about the N-aryl bond.10,12  This was reported by Mislow for acyclic and cyclic 
(ortho-tolyl)amides10 and the Curran group for their study on o-haloanilide atropisomers.11   
Thus, selected protein models were derived from small manipulations of the torsion 
balance side chains to realize the difference in energies of the pair-wise amino acid interactions.    
The two ortho sites of the top aromatic ring of the biaryl structure were altered to investigate 
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intramolecular hydrogen bonds and salt-bridge effects (1) by attaching different amino acids on 
each side or (2) by attaching side chains of different chain lengths.    
Both 1D and 2D NMR analysis indicated the presence of intramolecular hydrogen bonding 
and salt-bridge formation, in addition to solvent effects. Hydrogen bonding was promoted in 
toluene-d8.9  1H NMR and EXSY experiments were used to calculate the torsion balance rotational 
barriers.  The aryl-aryl bond between the upper and lower halves of the peptide hybrid torsion 
balance was determined to have a rotational barrier of 35.7 kcal∙mol-1 at 418 K.9   The N-aryl bond 
rotational barrier was calculated to be 20.9 kcal∙mol-1 at 343 K, while that of the neighboring N-
CO bond was only 17 kcal∙mol-1 at 298 K.9  Because of the large rotational barrier for the aryl-aryl 
bond, it was obvious that the rotation of the N-aryl bond was to be responsible for the 
conformational switch of the balance.  Although the scaffold has the overall shape necessary to 
match with the ends of an anti-parallel β-sheet, further investigation of the torsion balance structure 
was necessary.    
The goal of this project is to study the structure of the previously synthesized balance more 
closely.  Specifically, we planned to investigate the alignment of the o-methylene ether side chains 
of the top half of the balance to promote hydrogen bonding.  Modeling suggests that 90˚ (relative 
to the plane of the aromatic ring) is the best angle to provide alignment.  Thus, we proposed the 
incorporation of bromine atoms ortho to the aryl ether and o-methylenes.  Subsequent 1D and 2D 
NMR experiments can be utilized to determine if additional intramolecular hydrogen bonding 
occurs between the amino acids of the torsion balance.  The torsion balances of interest are shown 
in Figure 3.   
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Figure 3.  The conformationally controlled β-turn mimetic torsion balance target 
(1) and control analog (2). An example of one possible intramolecular hydrogen 
bonding pattern is shown in the folded state (left). 
 
The structure of 1 and 2 differ by the presence of bromines on the top ring of 1. Torsion 
balance 2 was determined to be the best control for the study to evaluate conformational effects 
from the bromines alone.  We hypothesize that 1 will form a stronger hydrogen bond than 2.  This 
study describes the synthesis toward targets 1 and 2.  
1.3 CONFORMATIONAL RESTRICTION OF SYNTHETIC DRUG TARGETS 
Structure-based drug design is often modeled after proteins and enzymes that participate 
in metabolic and/or cell signaling pathways that relate to disease.  Pharmaceuticals are envisioned 
to inhibit, restore, or modify the structure and behavior of disease-related proteins and enzymes. 
Protein fragments can be generated synthetically to mimic a protein system as exact copies, or as 
structurally modified derivatives, by incorporation of nonproteinogenic amino acid residues or by 
alteration of peptide backbone; however, several challenges have been faced in the area of peptide 
therapeutics, such as poor bioavailablility, proteolytic stability, and difficult cellular uptake.13-24 
3D structure elucidation is necessary for the development of new pharmaceuticals and is most 
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often derived from X-ray crystallography and 2D NMR studies.  Such data can provide valuable 
insights to the significance and nature of a given protein binding event.  Structure-based drug 
design (SBDD) has been successful by incorporating the structural and conformational features of 
peptides that are necessary for biological activity.  
The target protein’s well-defined “hotspot”, or binding pocket, is linked to a disease-
triggering pathway through its interaction with a small molecule or with a second protein or protein 
substructure. In SBDD, the goal is to optimize ligand structure to fit complementarily in a given 
binding pocket to disrupt the interaction responsible for the undesired biological cascade. The 
ligand-enzyme conformational complementarity is crucial for adequate potency and selectivity in 
synthetic drug targets.  Computational methods are relied upon for lead discovery and optimization 
through applying preferences from the Protein Data Base (PDB) and Cambridge Structural 
Database (CSD); however, predicting unbound ligand conformation is difficult for structures with 
rotatable bonds. The guiding principles of Lipinski’s small molecule approach to drug discovery 
are insufficient given the challenge of developing drugs against advanced PPI target classes. Yet, 
thoughtful consideration of substrate design can ensure conformational stability. Minimizing 
entropic barriers to intermolecular binding and to constraining intramolecular interactions, within 
the protein itself, lead to potential benefits such as increased selectivity and potency.   
A 2014 investigation by La Plante and coworkers16 uses a conformational control approach 
to design hepatitis C polymerase inhibitors. The study was designed to illuminate the effects of the 
molecular shape and mutual adaptions required to form and maintain bioactivity of a ligand-
enzyme pocket binding event. Initially a structural hinge was developed to form a class of diamides 
that would mimic the reported bioactive conformation; however, 2D NMR studies indicated that 
additional optimization of the diamide structure was needed. Substitution of the benzimidazole 
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unit with a more lipophilic indole was verified by 2D NMR analysis to realize their goal. Figure 4 
(reproduced from the literature)16 shows the constrained torsion angles and their folding 
preferences, as determined from 2D ROESY data. This work indicates how NMR-guided 
conformational restrictions and scaffold replacements are valuable strategies in drug design.   
 
Figure 4.  Structures, inhibition activities, and NMR ROESY data for La Plante’s  
redesign of the initial diamide series towards the development of hepatitis C virus 
polymerase inhibitors (reprinted from the literature).16  The ROESY data indicates the 
hydrogen bond distance information and subsequent conformational preference. 
Copyright (2012) Elsevier Ltd., Canada. 
 
Recent studies on anti-cancer therapeutics report on XIAP, an inhibitor family of interest 
with recent applications of novel strategies25-29 for conformational control between a globular 
protein and a continuous epitope, such as a β-turn.  The binding of tetrapeptide AVPI from Smac 
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to XIAP blocks the XIAP-Caspase 9 interaction that prevents cellular apoptosis.25  Strategies for 
conformational restriction have been imposed on the AVPI tetrapeptide through a bicyclic ring 
system that fuses the heterocycle of Pro to the neighboring Val to form a second ring.26-27  
Monfardini and coworkers28 developed a strategy to identify inhibitors against XIAP by 
identifying the anchoring residue (Ala of AVPI) from the bound motif; however, synthetic 
analogues designed by docking studies exhibited limited potency. With the goal of improving 
drug-like properties of lead compounds, Pellechia29 applied fragment-based design methods to 
XIAP, where virtual screening was again based on Ala of AVPI. Small fragments displaying weak 
binding interactions were identified by 2D NMR spectroscopy. The optimization of the resulting 
hit fragment generated a structure with a dissociation constant (KD) of 2.5 µM, compared to 0.58 
µM for XIAP-AVPI interaction,30  and with enhanced human plasma stability and permeability 
over the AVPI peptide.29 
For a given binding event, the conformation generally observed is that of a low energy 
state. Alternatively, the free ligand may assume lower energy conformations outside of the binding 
pocket. Such conformational constraints13-24 can be imposed to control configurational propensity 
of the unbound ligand to reflect the stability of its bound state, such as the cis-amide preference 
over the trns conformation. Cyclized amides, sulfonamides, and intramolecular hydrogen-bonded 
motifs have been installed to satisfy this requirement for mineralocorticoid receptor (MR) 
antagonists and for poly ADP-ribose polymerase (PARP) inhibitors as anti-cancer targets. 
Lotesta31 installed sulfonamide and lactam units to investigate Asn-770 binding for assessment of 
cis-amide mimetics in synthetic non-steroidal antagonists of MR.  PARP inhibitors designed by 
Wang and coworkers32 engage gly active site residues with an intramolecular hydrogen-bonded 
motif  in place of the cis-amide requirement of other PARP inhibitors.  
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In addition to mimicking cis-amide structures, sulfonamides are attractive for controlling 
molecular architecture in nuclear receptor modulators over linear amides, as recently shown for 
PPARγ partial agonism33 and for the induced-fit binding model to nuclear receptor RORγ34.  Other 
examples of conformational control exploit the axial preference of the α-substituent in biaryl 
systems for kinase inhibitors35 or the methyl effect, as done in biphenyl amide inhibitors of p38 
kinase from GSK36.  
Furthermore, the utility of various tools and methods measuring propensities of intra- and 
intermolecular interactions applied to SDBB, serves to enhance conformation to its preferred 
state.37 Given the additional factors influencing drug design, such as substrate flexibility and 
solvation, quantified energetic contributions as determined by conformational analysis, must be 
considered for successful SBDD.  
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2.0  SYNTHESIS OF THE TORSION BALANCE 
2.1 RETROSYNTHETIC ANALYSIS 
The primary target for our synthesis of a conformationally controlled β-turn mimetic 
torsion balance is depicted in Scheme 1 as biaryl amide 3.  The scaffold was initially designed 
with the same versatility of the original β-turn mimetic torsion balance (Figure 2) by allowing for 
independent amino acid couplings at three orthogonally protected positions. Yet, the synthesis of 
any hexa-substituted benzenoid target is challenging.  
In this project, two alternate routes to the balance were examined. Our first experiments 
were guided by the retrosynthetic plan presented in Scheme 1.  This plan was directed toward 
asymmetrical torsion balance analog 3. This target has orthogonally protected side chains at 
positions a, b, and c.  The pathway was based on installment of two different upper side chains 
before the aryl coupling to give an asymmetrical balance (Scheme 1).  In contrast, the second 
retrosynthetic analysis discussed here features addition of the upper side chains after the aryl 
coupling to form a symmetrical biaryl core of the balance (Scheme 2).  
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2.1.1 Retrosynthetic analysis of the asymmetrical torsion balance. 
Scheme 1.  Retrosynthetic pathway to the asymmetrical β-turn mimetic torsion balance. 
 
 
 The retrosynthesis of 3 involved an amide coupling of biaryl toluidine 4 with the Fmoc-
protected glycine chloride derivative,38 before subsequent deprotection and acylation. N-
methylation of the primary aniline from the reduced nitro group of 5 was proposed to produce 4.   
We envisioned that a Suzuki-Miyaura cross-coupling between bromide fragment 7 and boronic 
ester 8, followed by dibromination would afford asymmetrical biaryl 6. The retrosynthetic pathway 
for fragment 7 involved Fischer esterification39 of commercially available 4-bromo-3,5-
dihydroxybenzoic acid 9 prior to its treatment of two Williamson aryl ether synthetic protocols40 
to attach differential acetoxy side chains.  This synthesis, though not completed, remains of interest 
to us.  However, our central question regarding the effect of bromination on conformation could 
be answered more quickly using the simpler, symmetrical balance 11.  
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2.1.2 Retrosynthetic analysis of the symmetrical torsion balance.  
Scheme 2.  Retrosynthesis of the symmetrical β-turn mimetic torsion balance. 
 
 
Synthesis of symmetrical biaryl amide 11 was expected to proceed via an amide coupling 
of biaryl toluidine 12 with Fmoc-protected glycine chloride38 analog, before subsequent 
deprotection and acylation.  We envisioned nitro group reduction would readily give the primary 
aniline derivative needed to prepare 12 by N-methylation, preceded by Williamson aryl ether 
synthesis conditions.40  To obtain biaryl 13, we proposed the dibromination of the upper ring after 
Fischer esterification39 and after methoxy group cleavage of the Suzuki-Miyaura cross-coupling41 
product 14.  Bromide 15 was readily accessible from the methylation of commercially available 
4-bromo-3,5-dihydroxybenzoic acid 9.  Boronic ester 8 was prepared via Miyaura boration 
reaction of commercially available 2-bromo-6-nitrotoluene 10.42    
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2.2 STUDIES DIRECTED TOWARD SYNTHESIS OF THE ASYMMETRICAL 
TORSION BALANCE 
2.2.1 Synthesis of coupling fragment bromide 7. 
Scheme 3 depicts the synthesis of the coupling fragment bromide 7.9 Fischer 
esterification39 of commercially available 4-bromo-3,5-dihydroxybenzoic acid 9 afforded methyl 
benzoate 16 in 99% yield.  Ether 17 was synthesized by Williamson aryl ether synthesis40 on 16 
with 1 equiv of commercially available t-butyl bromoacetate in 35% yield.  The asymmetrical 
product 17 was separated from the symmetrical ether 17 via flash column chromatography.  The 
Williamson aryl ether synthesis protocol was again utilized to generate coupling fragment 7.  The 
product was afforded by coupling 18 with commercially available benzyl bromoacetate in a 
suitable 80% yield of 7. 
Scheme 3.  Synthesis of coupling fragment bromide 7. 
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2.2.2 Synthesis of arylboronic ester coupling fragment 8. 
Synthesis of the second coupling fragment, boronic ester 8, was the next challenge to be 
addressed before forming the core of the torsion balance.  Commerically available 2-bromo-6-
nitrotoluene 10 was subjected to Miyaura boration conditions42 with bis(pinacolato)diboron used 
as the boron nucleophile (Scheme 4).  Nitrotoluene 8 was chosen as the starting material, rather 
than its methylated aniline derivative,9 due to the amine incompatibility with the bromination step 
that would later be employed (Scheme 6). A similar procedure using additional 1,1’-
bis(diphenylphosphino)ferrocene (dppf) in dioxane also gave boronic ester 8 but with significantly 
lower yield.42b 
Scheme 4.  Miyaura boration of nitrotoluene 10. 
 
2.2.3 Steps towards the synthesis of asymmetrical biaryl 5. 
With both coupling fragments in hand, we next turned our attention to the Suzuki-Miyaura 
cross-coupling41 to give biaryl ether 6, which we then planned to brominate to afford the dibromo-
biaryl 5. We proposed that the coupling step should be done before bromination because of the 
coupling fragments exhibiting a total of three ortho-substituents and a meta-substituent; 
dibromination of 7 would not only increase the difficulty of the coupling reaction due to the 
presence of two additional meta-substituents but also decrease the yield because of competing 
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cross-couplings reactions.  In addition, cleavage of t-butyl ester could be observed due to its 
sensitivity to high temperatures if longer reaction times needed to be employed.   Treatment of 
fragments 7 and 8 with tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in toluene 
accompanied by Buchwald’s SPHOS® ligand41 afforded 6 with a yield of 34%.   
Scheme 5.  Suzuki-Miyaura cross-coupling of fragments 7 and 8. 
 
 
Now that biaryl ether 6 was constructed, dibromination ortho to the side chains was the 
next goal towards the core of the torsion balance.  Scheme 6 summarizes our attempts to produce 
the dibromo-biaryl 5 from 6.  It is difficult to predict where bromination will occur in this molecule 
due to the competing demands of electronic and steric effects.  In fact, no dibromination product 
(5) was isolated. Employment of substitution reaction conditions, entries 1-4, resulted in 
decomposition and cleavage of the t-butyl ester, indicated by the formation of t-butyl alcohol in 
1H NMR spectra.43  Addition of sodium acetate to suppress acidity by creating a buffer system was 
ineffective to form biaryl 5, even at increased reaction times. This may be due to the steric 
hindrance of the bulky side chains as well as the inductively less activating effects of the α-
benzyloxycarbonyl ethers.   
 
 
  
16 
 
 
Scheme 6.  Attempted dibromination of asymmetrical precursor 6. 
 
 
 
2.2.3.1  Model reactions for dibromination. 
 
In order to probe the stability of our substrate under acidic conditions and investigate other 
methodology to dibrominate 6, the symmetrical bromide fragment analog 19 was used for model 
bromination reactions (Table 1). Starting material and/or monobromination product 20 were 
observed in all entries. These results strengthen our argument that steric and electronic effects are 
mostly responsible for the poor reactivity of our substrate, as previously stated.  With the exception 
of entries 3, 7, and 8, formation of t-butyl alcohol was observed by 1H NMR of the crude product.43 
Only the procedure in Entry 3 provided dibromination product 21.  
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Table 1.  Results of model bromination reactions to test substrate stability under acidic 
conditions. 
 
 
 
Finally, the asymmetrical coupling fragment 7 was subjected to the entry 3 conditions 
described above (Scheme 7). The experiment revealed evidence (1H NMR and HRMS) of 
bromination occurring on the aryl ring of the benzyl ester to afford product 22 (21% yield). 
Scheme 7.  Bromination of asymmetrical coupling fragment bromide 7. 
 
Entry Conditionsa Yieldb 
1 Br2, AcOH, 3 h 0%c 
2 Br2, AcOH, 30 min 0%c 
3 Br2, AcOH/NaOAc, 24 h 29% 
4 Br2, AcOH/NaOAc,  3 days 0%c 
6 Br2, DCM, 1 h 0%c 
7 NBS, DCM, 2 days 0% 
8 NBS, Pd(OAc)2, AcOH,  6 h 0% 
9 NBS, Pd(OAc)2, AcOH, 80 ˚C, 12 h 0%c 
aReaction scale based on 0.22 mmol; all reactions were run at room temperature except entry 9.  
bIsolated yield of 21; recovered material also included 20 and starting material; ccleavage of t-butyl 
group observed by 1H NMR. 
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2.3 PREPARATION OF THE SYMMETRICAL BIARYL CORE OF THE TORSION 
BALANCE 
We learned from the above experiments that the dibromination of 6 was very slow, and 
would not be easily achieved without simultaneous bromination of the benzyl ester (similar to 
Scheme 7). Furthermore, we learned that the t-butyl ester was sensitive to the bromination 
conditions (Table 1).  Therefore, we turned to a modified synthetic route to meet our goal (Scheme 
1).  
This pathway of the conformationally controlled β-turn mimetic torsion balance began with 
preparation of the biaryl core of the balance.  This involved cross-coupling bromide 15 and boronic 
ester 8 using the same conditions for the Suzuki-Miyaura reaction as before to give 14 with a good 
yield of 74% (Scheme 8).  The increase in percent yield (from 34% in Scheme 5) is most likely 
due to the less sterically hindered methoxy side chains of 14 than the bulky side chains of coupling 
fragment 7.  
 
 
Scheme 8. Successful Suzuki-Miyaura cross-coupling of fragments 15 and 8. 
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The synthesis of 5 was straightforward, using 3 equiv of dimethylsulfate (DMS) to 
methylate commercially available 4-bromo-3,5-dihydroxybenzoic acid 7 in quantitative yield 
following recrystallization (Scheme 9).44a  An alternative procedure using methyl iodide also gave 
benzoate 5 from the Fischer esterification33 product 13, but with a slightly lower yield of 85%.44b 
Scheme 9.  Syntheses of coupling fragment bromide 15. 
 
 
Attempted Suzuki-Miyaura cross-couplings of other top fragments (16 and 23) were first 
tried in efforts to form the biaryl core of the balance, using the same conditions as before (Scheme 
10).33 Failure to directly form biaryl from cross-coupling fragments 16 and 8 was most likely due 
to the phenols undergoing deprotonation in the presence of base.  Next, cross-coupling of the silyl 
ether product 23 and 8 was attempted to give biaryl 25.  This too was unsuccessful. We believe 
the t-butyl silyl ethers sterically interfered with the C-C bond formation.  Despite the methyl ester 
on coupling fragment 15, the methyl ether was deduced to be the best protecting group for the 
diphenol due to its facile preparation and the exceptional yield of the cross-coupling reaction.   
Scheme 10. Failed Suzuki-Miyaura cross-couplings. 
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Now that the biaryl building block was in hand, ether cleavage was the next goal before 
functionalizing the top of the balance.  We had hoped to execute a selective cleavage of the methyl 
ethers using magnesium iodide (MgI2) in an ionic liquid to obtain the dihydroxy-biaryl 24.45 
Treatment of biaryl 14 with 3 equiv of freshly prepared MgI45c in 1-butyl-3-methylimidazolium 
tetrafluoroborate ([bmim]BF4) ionic liquid at 50 ˚C from 7 to 24 h resulted only in reisolation of 
starting material (Scheme 11).45c  
 
Scheme 11. Attempted selective demethylation of aryl methyl ether. 
 
2.3.1 Model reactions for demethylation of biaryl ether 14. 
Consideration of the drawbacks of aryl methyl ether cleavage procedures led us to conclude 
that ether cleavage without ester cleavage was unlikely.46   We then envisioned a two-step reaction 
sequence of non-selective demethylation and successive Fischer esterification to afford dihydroxy-
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biaryl 24. Results of model experiments with coupling fragment 15 can be found in Table 2.  
Starting material was recovered in the majority of the reactions along with partially cleaved 
products 26 and 27 (entries 1-9). However, treatment with BBr346 resulted in successful 
demethylation to yield benzoic acid 9 at 85% (entry 10).  In the crucial experiment, subjecting 
biaryl 14 to 6 equiv of BBr3 in DCM followed by immediate Fischer esterification of the acid 
readily produced dihydroxy-biaryl ester 24 in 78% yield. 
 
 
 
Table 2. Conditions and yields for model demethylation reactions. 
 
 
     Entry Conditionsa Yieldb 
1 NaI, 15-crown-5, BBr3, DCM, -40 ˚C, 5 hours 0% 
2 ethanethiol, AlCl3, rt, 1.5 hours 0% 
3 NaCN (6 eq), DMF, 90 ˚C, 20 hours  74%c 
4 NaCN (15 eq), DMF, 90 ˚C, 24 hours  67%c 
5 NaI, (CH3)3SiCl, ACN, 50 ˚C, 20 hours 48%c 
6 NaI, (CH3)3SiCl, ACN, 50 ˚C, 40 hours 34%c 
7  methanesulfonic acid, 90 ˚C, 20 hours  0% 
8  NaI, methanesulfonic acid, 90 ˚C, 20 hours  33%c 
9 NaI, 15-crown-5, BBr3, DCM, -40 ˚C, 9 hours 0% 
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10 BBr3, DCM, 0 ˚C to rt, 7 hours 85%d 
aReaction scale based on 0.04-0.08 mmol of 15.  bYield of major product determined by 1H 
NMR; recovered material also included SM.   cYield of 9.  dYield of 26.  eYield of 27. 
 
Scheme 12.  One-pot synthesis of demethylated biaryl analog 24.° 
 
 
We next endeavored to carry out the bromination of the dihydroxy-biaryl ester 24.  This 
intermediate was an improved substrate for dibromination due to the presence of more strongly 
electron-donating hydroxyl groups, rather than the inductively less activating β-
benzyloxycarbonyl ether groups.  Steric effects are minimized in comparison to substrate 6 as well.   
2.3.2 Model reactions for dibromination of the diphenol biaryl 24. 
Our efforts to determine the best methodology to afford dibromo analog 13 are summarized 
in Table 3.  We first subjected model substrate 7 to 2.5 equiv of Br2 in AcOH/NaOAc buffer, as 
previously used on biaryl 12 (entry 1).43 After 24 hours, 26 was afforded in 83% yield.  We had 
earlier observed cleavage of t-butyl esters under these conditions, when ethers, rather than 
hydroxyls were present. To support future studies, we looked for a faster bromination process that 
might be more compatible with t-butyl esters.    
Solvent substitution effects were investigated for the treatment of 14 with Br2. A 6:1 
solution of CH3Cl:CH3CN afforded 26 in 70% yield after only 6 hours (entry 2) and extending the 
reaction time to 24 hours only increased the yield by 5% (entry 3).47   Substitution of CCl4 as the 
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reaction solvent produced 26 in 82% yield after only 2 hours (entry 10).48  An increased reaction 
time of 18 hours, slightly lowered the yield to 76% (entry 9).  Other reported conditions were not 
further investigated because of the significantly lower yields. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  Conditions and yields for model dibromination reactions. 
 
 
Entry Conditionsa Yieldb 
1 Br2, AcOH/NaOAc, 24 h 83% 
2 Br2, 6:1 CH3Cl:ACN,  6 h 70% 
3 Br2, 6:1 CH3Cl:ACN,  24 h  75% 
4 NBS, ACN, 24 h 0% 
5 NBS, ACN, 48 h 8% 
6 Br2, FeCl3, DCM, 12 h 43% 
7 Br2, FeCl3, DCM, 20 h 55% 
8 NH4Br, H2O2, AcOH, 16 h 0% 
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9 Br2, CCl4, 18 h 76% 
10 Br2, CCl4, 2 h 82% 
aReaction scale based on 0.1 mmol of 16; all reactions were performed at room temperature.  
bYield of 28 as determined by 1H NMR; recovered material also included 29 and SM. 
2.4 SYNTHESIS OF THE SYMMETRICAL TORSION BALANCE 
Based on the model bromination experiments, we chose to try Br2 in CCl4 for the 
bromination of the phenol.  Treatment of 24 with 2.5 equiv of Br2 in CCl4 afforded dibromination 
product 13 in 76% yield (Scheme 13).47 With the preparation of the core almost complete, 
etherification was the only remaining step before functionalizing the bottom portion of the balance 
(Scheme 13).   Treatment of 13 with 2 equiv of commercially available benzyl bromoacetate by 
the Williamson aryl ether protocol afforded the symmetrical intermediate 30 in 80% yield.  Several 
methods were then considered for the reduction of the nitro group to its amine derivative 31.   
Scheme 13.  Steps towards constructing the symmetrical torsion balance core. 
 
 
2.4.1 Model nitro group reductions. 
We employed 32 as a model for biaryl 30 while evaluating reduction methods.  
Etherification conditions as used before were employed to generate 32 from commercially 
available nitrotoluene 33 in 89% yield.  The reduction of 32 by H2/PtO2 produced 34 in 42% yield 
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at 1.5 hours (entry 1, Table 4) and 55% yield at 3 hours (entry 2).48a  Employment of SnCl2 with 
MeOH in DCM afforded 34 in 24% at 16 hours, but decomposition was also observed (entry 3).48b  
Reaction of 32 with Fe in the presence of AcOH and MeOH provided 34 at 29% (entry 5),48c while 
reduction with Zn and HCl48d  in ethyl acetate gave an excellent yield of 92% (entry 5). Only 
decomposition was observed for entries 6 and 7.48e,f 
 
 
 
 
 
 
 
Table 4.  Results of model nitro group reductions. 
 
 
Entry Conditionsa Yieldb 
1 H2, PtO2, ethyl acetate, rt, 1.5 h 42% 
2 H2, PtO2, ethyl acetate, rt, 3 h 55% 
3 SnCl2, MeOH, DCM, 0 ˚C to rt, 16 h 24%c 
4 Fe, AcOH, MeOH, DCM, 40 ˚C, 3 h 29% 
5 Zn, HCl, ethyl acetate, 0 ˚C to rt, 16 h 92% 
6 hydrazine hydrate, FeSO4·7H2O, EtOH, H2O, reflux, 15 h 0%c 
7 Zn, formic acid, MeOH, rt, 3 h 0%c 
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aReaction scale based on 0.17 mmol of 33.  bIsolated yield of 34; recovered material also 
included SM except for entries 2, 3, and 5.  cDecomposition observed. 
 
With the results from the model reactions in hand, we returned to our biaryl substrate.  
Reduction of biaryl 30 by Zn/HCl gave an excellent yield of 30 at 80% (Scheme 14).  Alternatively, 
treatment with H2/PtO2, gave only debenzylation product 35, unlike the model, at 39% yield with 
the nitro group still intact.  Despite the unsuccessful result, this reaction was able to serve as a 
model for the future debenzylation step.   
 
Scheme 14.  Nitro group reduction to obtain biaryl toluidine 31. 
 
 
2.4.2 Final steps to the symmetrical torsion balance core. 
2.4.2.1 Methods for mono N-methylation.  
We then turned to the alkylation of toluidine 31. Liberatore had previously designed an 
indirect N-methylation procedure based on partial protection of the aniline (Scheme 15).9    
Reaction of di-tert-butyl dicarbonate (Boc anhydride, or Boc2O) with 31 gave protected derivative 
36.  Alkylation by treatment with MeI and NaH in DMF resulted in a complex mixture of products 
as observed by TLC and 1H NMR. Boc group cleavage with TFA afforded the methylation 
products 12, 37, and 38.   
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Scheme 15. Boc protection, methylation, and deprotection of toluidine 31. 
 
 
In efforts to elucidate the mechanism for the formation of 37 and 38, we turned to model 
reactions of the Boc-protected derivative of aniline 34 to observe the effects between order of 
addition of MeI and NaH.  The conversion of benzyl to methyl ester was only noted when NaH 
was added prior to MeI.  Thus, we concluded that the side products were a result of benzyl ester 
hydrolysis. All precautions were then taken to eliminate the presence of water during the 
methylation of 31, but only in one instance was desired methylated carbamate provided to give 12 
in 20% yield, after Boc group cleavage.  However, replication was unsuccessful.  We suspected 
this was due to the initial presence of the hydroxide ion in the reaction.  Potassium hydride was 
also substituted as base but did not have any effective increase in yield.   
We examined another route to improve the yield and consistency of results (Scheme 16). 
Protection of 31 was achieved with commercially available 4-nitrobenzenesulfonyl chloride 
(NsCl) to generate its sulfonamide derivative 39, which was subsequently treated with 
diazomethane.49-51  The advantage of using the nosyl protecting group was to furnish a sulfonamide 
of exceptional acidity.  This is known to increase the rate of formation of the methyl diazonium 
ion.50,51 Commercially available N-methylurea 40 was used to generate the N-methyl-N-
nitrosourea 41 and reacted with KOH directly before the alkylation step.49a  Cleavage of the 
protecting group was attempted using mercaptoacetic acid and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) in CH3CN at 50 ˚C but was unsuccessful at 4 and 6 hours.  After increasing reaction time 
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to 20 hours, evidence of dimerization of 12 was confirmed by HRMS.  This was attributed to the 
instability of the alkylated intermediate under prolonged heat in the presence of DBU.  
 
Scheme 16.  Attempted N-methylation of 39 with diazomethane.  
 
 
 
With the N-methylation proving more difficult than anticipated, we turned to an approach 
based on Katritzky’s methods for the mono N-alkylation of anilines by Mannich reaction.52  A two 
step reaction sequence was envisioned to achieve 12. This involved aminomethylation of 31 with 
benzotriazole and formaldehyde, followed by subsequent reduction of the base with sodium 
borohydride. The described condensation procedure gave low and inconsistent yields, probably 
due to poor solubility of aniline 31 in EtOH, even after sonication.  Formation of various 
byproducts was a direct result of the inability to control the imminium ion forming equilibrium at 
low reaction concentration. The substitution of THF for the reaction solvent led to prolonged 
reaction rates and an increase in byproducts. The dimethylaniline derivative (not shown) was 
observed by 1H NMR and by HRMS on both biaryl substrate 31 and model substrate 34 after their 
reduction.   
To improve the method described above, the reaction was modified by direct condensation 
of 1-hydroxymethylbenzotriazole 42 with aniline 31 (Scheme 17).53  This removed one uncertainty 
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(the formalin reaction and related equilibria) in the process. Addition of benzotriazole 43 to 
formaldehyde in EtOH provided 42, which was also converted to 1-chloromethylbenzotriazole by 
treatment with thionyl chloride.52  In using model compound 34 as our substrate, treatment with 
42 produced higher yields than the chloro-derivative, even in the presence of lithium iodide.  
Finally, condensation of 42 with biaryl 31 led to direct isolation of condensation product, which 
was readily reduced with NaBH4 to afford the torsion balance core 12 in 53% yield. Effects of 
solvent substitution on the alkylation were also examined, as was catalysis by pyridinium p-
toluenesulfonate, but no significant correlation with product yield was observed. 
 
 
 
 
 
 
 
Scheme 17.  Two-step sequence for mono N-methylation of biaryl toluidine 31. 
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2.4.2.2  Amino acid coupling, deprotection, and acylation. 
Our focus now turned to the amidation step remaining en route to finalizing the torsion 
balance (Scheme 18).  The approach was based on Carpino’s conditions,38 initially converting 
commercially available N-9-fluorenylmethyloxycarbonyl-glycine (N-Fmoc-gly) 44 to its 
corresponding acid chloride 45 with thionyl chloride, which was coupled with biaryl 12 
immediately after its formation due to its susceptibility to hydrolysis.  Amide 46 was isolated in 
67% yield.  The final step to synthesize torsion balance 11 involved treatment of 46 with piperidine 
in DMF to deprotect the amino acid, followed by immediate acylation with acetic anhydride and 
pyridine (70% yield). 
Scheme 18.  Final steps to synthesize torsion balance 11. 
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3.0  INITIAL NMR STUDIES OF THE TORSION BALANCE 
3.1 ANALYSIS OF TORSION BALANCE FOLDING PREFERENCE  
3.1.1 Folding preference of torsion balance 11. 
After attaining torsion balance 11, it was imperative to examine our conformationally 
controlled scaffold for improved antiparallel β-sheet configuration and hydrogen bonding distance.  
With this analog being symmetrical, we could only investigate the ability of the amino acid proton 
to hydrogen bond with the benzyl ester carbonyl. Previous line shape analysis and EXSY 
experiments on the asymmetrical first generation balance (Figure 1) had determined that the aryl-
aryl bond rotational barrier was 35.7 kcal∙mol-1 with a half-life of 2.2 days at 418 K and that of the 
N-aryl bond to be 20.9 kcal∙mol-1 at 298 K.9  Due to the presence of the ortho methyl substituent 
to the carbamate, the N-CO amide bond barrier to rotation (17 kcal∙mol-1 at 298 K) was larger than 
expected based on results with Smith’s carbamates.54 Yet, with the second generation balance 
being symmetrical, the N-CO amide bond is the only site to invoke a conformational switch, as 
illustrated in Figure 5.  The significance of the NMR analysis of the benzyl ester carbonyls can be 
realized when investigating folding preference and hydrogen bond selectivity in isomers of more 
advanced symmetrical torsion balances.    
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Figure 5.  Two conformers of glycine target 11 by rotation around the N-CO amide 
bond. 
 
The N-CO bond rotation affords the E and Z conformers of torsion balance 11 that are 
illustrated in Figure 5.  The presence of the two conformations is evident from the two N-methyl 
group singlets in the 1H NMR spectra of 11 at 298 K in both CDCl3 and CD2Cl2 (Figure 6).   A 
15:1 ratio of the two N-methyl group singlets can be observed in both solvents; the chemical shift 
in CDCl3 is slightly more downfield (δ = 3.25 ppm) than in CD2Cl2 (δ = 3.21 ppm). This result 
confirms that rotation around the N-CO amide bond is responsible for both conformers.     
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Figure 6. 1H NMR spectra of glycine target 11 in CDCl3 (bottom) and CD2Cl2 (top) at 298 K. 
 
The 1H NMR data reveal approximately the same ratio of E and Z rotamers about the N-
CO amide bond as found for first generation balances (93% to 7%).9  The 2D NMR ROESY data 
confirm that (E)-11 is the major rotamer (94%) and (Z)-11 is the minor rotamer (6%).    
Based upon the configuration of the major component, the position of the amino acid amide 
proton appears to be within range to hydrogen bond to the carbonyl of the upper side chain for 
more advanced torsion balances.  Thus, suggesting the conformationally controlled torsion balance 
scaffold may be an improved design for antiparallel β-sheet folding. 
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4.0  CONCLUSION 
We report herein the synthesis of the core scaffold of a new conformationally controlled 
torsion balance that can be applied toward quantitative comparison of side chain interactions in 
the antiparallel β-sheet motif.   The design has previously shown a restricted N-aryl bond rotation 
to impose a two-state folding manifold to mimic the potential folding dynamics of a β-turn.  
However, the dibromo design features an additional degree of conformational control by the 
incorporation of the bromo substituents ortho to the upper side chains.  With the synthesis and 
analysis of 1H and 2D ROESY NMR results of 11, we conclude the torsion balance core scaffold 
has improved chain alignment between the top and bottom side chains to ultimately promote 
hydrogen bond formation in the final targets.  
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5.0  EXPERIMENTAL 
Thin layer chromatography (TLC) was performed on E. Merck 60F 254 (0.25 mm) 
analytical glass plates.  A Thomas Hoover capillary melting point apparatus was used to obtain 
melting points and are uncorrected. A Nicolet Avatar 360 FT-IR was utilized to determine infrared 
(IR) spectra. Bruker Avance 300, 400, and 500 MHz spectrometers were used to find proton and 
carbon nuclear magnetic resonance spectra (1H and 13C NMR).  TMS (1H) or residual solvent (13C) 
peak were set as the reference value to report chemical shifts in parts per million (δ).  1H NMR 
data was taken at room temperature (21 – 27 ˚C) and is reported using the following list of 
abbreviations: s = singlet; d = doublet; t = triplet; q = quartet; dd = doublet of doublets; m = 
multiplet; ABq = AB quartet; quartet of doublets = qd. High resolution mass spectra were recorded 
on a VG 7070 spectrometer.  Percent yields are for material of >95% purity as indicated by 1H 
NMR spectra. 
Dry solvents were obtained prior to use by distilling the solvents from the appropriate 
drying agent under nitrogen atmosphere.  DCM was distilled from CaH2, toluene was distilled 
from CaCl2, DMF was vacuum distilled from 4 Å molecular sieves, and diethyl ether and THF 
were distilled from sodium metal and benzophenone.  Dry CCl4 and DMSO were purchased from 
Aldrich and used as supplied.  “Removal of volatile components under reduced pressure” refers to 
rotary evaporation of the sample at 21-65 °C at a pressure of 18-25 mm Hg followed by treatment 
under high vacuum (0.1 mm Hg) at room temperature.   
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5.1 EXPERIMENTAL PROCEDURES 
O OtBu
O
NO2
O O
BnO
CO2CH3
 
Methyl 2,6-dimethoxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (6).  In a round-bottom 
flask, 0.17 g (0.34 mmol) of benzoate 7, 0.14 g (0.55 mmol) of boronic ester 8, 0.013 g (0.014 
mmol) of Pd2(dba)3, 0.022 g (0.055 mmol) of 2-dicyclohexylphosphino-2’,6’-dimethoxybiphenyl 
(SPhos), and 0.24 g (1.03 mmol) of (ground) PO4•H2O were added and dried under reduced 
pressure for 5 minutes and backfilled with nitrogen two times.  Toluene (3 ml) was added, and the 
solution was degassed using the freeze-pump-thaw method three times under a nitrogen 
atmosphere.  The flask was sealed; the reaction mixture was stirred at 90 °C for 18 h, and cooled 
to room temperature.  The mixture was diluted with DCM (30 mL) and H2O (30 mL); the organic 
layer was extracted, and the aqueous layer was washed with additional DCM (3 x 30 mL).  The 
combined organic layers were dried over MgSO4 and filtered, and volatile components were 
removed from the filtrate under reduced pressure to give a brown crude oil.  The oil was purified 
by flash chromatography (SiO2, hexanes/ethyl acetate, 5:1) to afford 0.13 g (67.6%) of 6 as a white 
foam: Rf   0.36 (hexanes/ethyl acetate, 4:1); IR (thin film, cm-1) 3442, 2979, 1751, 1725, 1581, 
1528, 1437, 1422, 1354, 1330, 1236, 1194, 1136; 1082, 1029, 999, 867, 844, 810, 771, 741, 698; 
1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8 Hz, 1H), 7.42 (d, J = 7 Hz, 1H), 7.33 (broad s, 4H), 
7.27 (broad s, 2H), 7.19 (s, 2H), 5.16 (s, 2H), 4.67 (s, 2H), 4.49 (s, 2H), 3.91 (s, 3H), 2.27 (s, 3H), 
1.44 (s, 9H); 13C NMR (400 MHz, CDCl3) δ 168.2, 167.4, 166.2, 156.2, 155.9, 150.8, 136.2, 135.3, 
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135.1, 132.8, 131.5, 128.8,128.6, 126.0, 123.9, 122.5, 106.5, 106.0, 82.9, 67.3, 66.0, 65.4, 52.6, 
28.2, 16.5; HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C30H31NO10Na 588.1840, found 588.1854.  
O O
Br
OtBu
O
BnO
O
CO2CH3
 
Methyl 3-(2-(benzyloxy)-2-oxoethoxy)-4-bromo-5-(2-tert-butoxy-2-oxoethoxy) benzoate (7).  In 
a round bottom flask, 0.49 g (1.36 mmol) of benzoate 18, 0.26 mL (1.63 mmol) of benzyl 
bromoacetate, 0.22 g (1.63 mmol) of K2CO3, and 0.08 g (0.33 mmol) of 18-crown-6 were dissolved 
in acetone (35.4 mL), and the reaction mixture was refluxed for 24 h.  The volatile components 
were removed under reduced pressure, and the residue was diluted with DCM (25 mL) and water 
(25 mL); the organic layer was extracted, and the aqueous layer was washed with additional DCM 
(3 x 25 mL).  The combined organic layers were dried over MgSO4 and filtered, and the volatile 
components were removed from the filtrate under reduced pressure to give a crude yellow oil.  The 
oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 
7:1/6:1/3:1) to yield 0.55 g (80.2%) of 7 as a white solid: Rf  0.48 (hexanes/ethyl acetate 3:2); mp 
68-70 °C; IR (thin film, cm-1) 2978, 1753, 1724, 1587, 1423, 1369, 1337, 1241, 1194, 1133, 1029, 
1000, 844, 763;  1H NMR (400 MHz, CDCl3) δ 7.24 (s, 5H), 7.04 (d, J = 4 Hz, 2H),  5.14 (s, 2H), 
4.70 (s, 2H), 4.56 (s, 2H), 3.77 (s, 3H), 1.40 (s, 9H); 13C NMR (500 MHz, CDCl3) δ 167.8, 166.9, 
165.9, 155.8, 155.7, 149.9, 149.1, 143.4, 141.7, 140.0, 135.0, 130.5, 130.0, 128.7, 128.6, 128.6, 
128.5, 128.5, 108.2, 107.4, 107.2, 82.9, 67.3, 67.2, 66.6, 66.3, 60.7, 52.5, 28.0; HRMS (ESI-TOF) 
m/z: [M+Na]+ calcd for C23H25O8NaBr 531.0630, found 531.0663. 
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O B
O
NO2
 
4, 4, 5, 5-tetramethyl-2-(2-methyl-3-nitrophenyl)-1,3,2-dioxaborolane (8).  To a third flame-dried 
200 ml round-bottom flask, 3.00 g (13.9 mmol) of 10, 5.29 g (20.8 mmol) of (Bpin)2, 4.09 g (41.7 
mmol) of KOAc, and 0.45 g of [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II), 
complex with DCM (Pd(dppf)Cl2•DCM; 0.56  mmol) were added.  The reaction flask was then 
placed on vacuum line for 5 minutes and backfilled with nitrogen and repeated.   DMSO (83.2 mL) 
was then added and the solution degassed using the freeze-pump-thaw method three times under 
a nitrogen atmosphere.   The flask was sealed; the reaction mixture was stirred at 90 °C for 20 
hours and then cooled to room temperature.  The reaction mixture was then diluted with DCM 
(100 mL) and H2O (100 mL).  The organic layer was extracted and washed with H2O (3 x 100 
mL).  The aqueous layer was washed with additional DCM (2 x 100 mL).  Organic extracts were 
combined, and the volatile components were removed from the filtrate under reduced pressure to 
give a brown crude oil.  The oil was purified twice by flash column chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient (2 columns) 10:1/6:1; then 30:1) to give 2.7 g (76%) of 8 
as a pale yellow solid: Rf   0.89 (hexanes/ethyl acetate, 4:1); mp 52-53 °C; IR (thin film, cm-1) 
3055, 2982, 2933, 1603, 1569, 1527, 1474, 1439, 1344, 1267, 1214, 1144, 1109, 1026,1078, 963, 
786, 739, 669, 579. 463; 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 7 Hz, 1H), 7.77 (d, J = 8 Hz, 
1H), 7.27 (t, J = 8 Hz, 1H), 2.67 (s, 3H), 1.36 (s, 12H); 13C NMR (300 MHz, CDCl3) δ 151.3, 
139.9, 138.2, 126.3, 126.0, 84.4, 25.0, 18.0; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C13H19BNO4 
264.1407, found 264.1405.37b 
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Dibenzyl 2, 2’-((3’-(2-acetamido-N-methylacetamido)-3,5-dibromo-4-(methoxycarbonyl)-2’-
methyl-[1, 1’-biphenyl]-2,6-diyl)bis(oxy))diacetate (11).  To 0.01 g (0.01 mmol) of 46 in a round-
bottom flask was added 0.045 mL of a 20% piperidine/DMF solution, and the reaction mixture 
was stirred at room temperature for 20 min.  Then 0.24 mL (mmol) of acetic anhydride and 0.71 
mL (mmol) of pyridine were added, and the solution was stirred at room temperature for 30 min. 
The volatile components were removed from the filtrate under reduced pressure to give a yellow 
oil. The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate/methanol elution 
gradient 1:1:0/2:3:0/0:1:0/0:9:1) to give 0.007 g (76%) of 11 as a white foam: Rf 0.34 (100% ethyl 
acetate); IR (thin film, cm-1) 3338, 2932, 1751, 1723, 1655, 1580, 1423, 1393, 1369, 1329, 1235, 
1193, 1135, 1029, 996, 844, 806, 733; 1H NMR (700 MHz, CDCl3) δ 7.34-7.27 (m, 8H), 7.22-7.19 
(m, 4H), 7.14-7.13 (m, 1H), 6.26 (broad s, 1H), 5.07 (s, 2H), 5.02 (s, 2H), four protons of 
conformers: [4.25, 3.96 (qAB, J = 15 Hz), 4.20, 4.15 (qAB, J = 15 Hz)], 4.02 (s, 3H), two protons 
of conformers: [3.65 (qd, J = 4.9 Hz), 3.35 (s)], 3.15 (s, 3H), 2.01 (s, 3H), 1.95 (s, 3H); 13C NMR 
(500 MHz, CDCl3) δ 170.0, 169.0, 167.2, 167.1, 166.1, 153.5, 141.6, 139.6, 136.4, 135.6, 135.3, 
133.9, 131.4, 131.3, 127.8, 111.7, 111.3, 69.5, 67.4, 67.1, 53.7, 42.2, 36.3, 23.4, 15.3; HRMS (ESI-
TOF) m/z: [M+CHO2]- calcd for C39H37O12N2Br2 885.0700, found 885.0709. 
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Dibenzyl 2,2’-((3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-3’-(methylamino)-[1,1’-biphenyl]-
2,6-diyl)bis(oxy))diacetate (12).  0.1 g (0.14 mmol) of 31 and 0.025 g (0.17 mmol) of 42 in THF 
(0.1 mL) were sonicated for 5 minutes to give a homogenous solution.  The mixture was then 
diluted with EtOH (0.16 mL) and stirred at room temperature for 12 h.   Volatile components were 
removed under reduced pressure, and reaction vial was cooled to 0 °C for 10 minutes.  The residue 
was rinsed with chilled, dry DCM followed by hexanes to produce an off-white solid.  The 
precipitate was isolated and taken up into DCM, dried over K2CO3, filtered, and volatile 
components were removed under reduced pressure to give an off-white solid. The dry intermediate 
was dissolved in THF (0.3 mL), and 0.01 g (0.18 mmol) of NaBH4 were added and stirred for 14 
h.  The reaction mixture was concentrated under reduced pressure and the residue was diluted with 
ice, cold H2O, and DCM; the organic layer was extracted and aqueous layer washed with additional 
DCM (2 x 4 mL).  The combined organic layers were washed with additional H2O (5 mL) and 
then brine (5 mL); the organic layer was dried over MgSO4, filtered, and volatile components were 
removed from the filtrate under reduced pressure to give a yellow foam.  The foam was purified 
by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 7:1/6:1) to yield 0.040 g 
(41%) of 12 as a white foam: Rf  0.38 (hexanes/ethyl acetate 2:1; IR (thin film, cm-1) 3432, 3059, 
2978, 2303, 2053, 1648, 1420, 1375, 1241, 1122, 892, 743; 1H NMR (400 MHz, CDCl3) δ 7.33 
(broad s, 5H), 7.26 (broad s, 5H), 7.12 (t, J = 8 Hz, 1H), 6.59 (d, J = 8 Hz, 1H), 6.53 (d, J = 8 Hz, 
1H), 5.04 (s, 4H), 4.12, 4.00 (ABq, J = 15 Hz, 4H) 4.01 (s, 3H), 3.66 (broad s, 2H), 2.87 (s, 3H), 
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1.86 (s, 3H); 13C NMR (500 MHz, CDCl3) δ 167.7, 166.4, 153.7, 147.9, 138.7, 135.5, 132.3, 131.1, 
128.9, 128.8, 128.6, 127.2, 121.4, 119.2, 111.0, 109.9, 69.4, 67.0, 53.6, 31.2, 30.1, 28.7, 14.6, 14.5; 
HRMS (ESI-TOF) m/z: [M+H]+ calcd for C34H32Br2NO8 742.0495, found 742.0496. 
OH
NO2
HO
CO2CH3Br Br
 
Methyl 3,5-dibromo-2,6-dihydroxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (13).    In 
an oven-dried round-bottom flask, 0.26 ml (4.12 mmol) of Br2 in CCl4 (2.9 mL) was added 
dropwise over 30 min to a stirred solution of 0.52 g (1.72 mmol) of 14 in CCl4 (7 mL) in the dark.  
The reaction mixture was stirred for 1 h.  Saturated NaHSO3 was then added until red color 
dissipated.  Mixture was diluted with ether (30 mL) and organic layer was extracted.  The aqueous 
layer was washed with additional ether (2 x 30 mL).  The combined organic layers were washed 
with brine (75 mL), dried over MgSO4 and filtered, and the volatile components were removed 
from the filtrate under reduced pressure to yield a brown oil.  The oil was purified by flash column 
chromatography to give 0.60 g (76%) of 13 as an off-white foam: Rf    0.36 (hexanes/ethyl acetate, 
4:1); mp 158-159 °C; IR (thin film, cm-1) 3431, 2101, 1642, 1264, 790; 1H NMR (400 MHz, 
CDCl3) δ 7.90 (dd, J = 7, 2 Hz, 1H), 7.44-7.39 (m, 2H), 5.91 (broad s, 2H), 4.02 (s, 3H), 2.28 (s, 
3H); 13C NMR (600 MHz, CDCl3) δ 166.0, 151.1, 150.5, 137.0, 135.0, 134.6, 132.9, 126.8, 124.9, 
115.7, 99.3, 53.7, 16.4; HRMS (ESI-TOF) m/z: calcd for C15H11NO6Br2 461.8900, found 
461.8882. 
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OCH3
NO2
H3CO
CO2CH3
 
Methyl 2,6-dimethoxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (14).  In a round-bottom 
flask, 1.45 g (5.29 mmol) of benzoate 15, 2.08 g (7.94 mmol) of boronic ester 8, 0.19 g (0.21 
mmol) of Pd2(dba)3, 0.35 g (0.85 mmol) of SPhos, and 3.66 g (15.87 mmol) of K3PO4•H2O 
(ground) were added and dried under reduced pressure for 5 minutes and backfilled with nitrogen 
two times.  Toluene (30 ml) was added, and the solution was degassed using the freeze-pump-thaw 
method three times under a nitrogen atmosphere.  The flask was sealed; the reaction mixture was 
stirred at 90 °C for 18 h and cooled to room temperature.  The mixture was diluted with DCM (150 
mL) and H2O (150 mL); the organic layer was extracted, and the aqueous layer was washed with 
additional DCM (3 x 150 mL).  The combined organic layers were washed with brine (200 mL), 
dried over MgSO4 and filtered.  Volatile components were removed from the filtrate under reduced 
pressure to give a reddish brown crude oil.  The oil was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient, 8:1/6:1) to give 1.19 g (74%) of 14 as a pale yellow solid: 
Rf  0.28 (hexanes/ethyl acetate, 4:1); mp 119-120 °C; IR (thin film, cm-1) 3436, 2919, 2881, 1721, 
1580, 1527, 1456, 1434, 1409, 1351, 1326, 1242, 1126, 997, 770; 1H NMR (400 MHz, CDCl3) δ 
7.84 (dd, J = 6, 3 Hz, 1H), 7.36-7.34 (m; 4H), 3.97 (s ,3H), 3.78 (s, 6H), 2.20 (s, 3H); 13C NMR 
(400 MHz, CDCl3) δ 167.0, 157.7, 150.9, 137.0, 135.4, 132.6, 131.8, 126.1, 123.8, 121.8, 105.4, 
56.3, 52.7, 16.4; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C17H18NO6 332.1134, found 332.1124. 
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CO2CH3
H3CO OCH3
Br  
Methyl 4-bromo-3,5-dimethoxybenzoate (15). To a stirred solution of 2.50 g (10.7 mmol) of 
carboxylic acid 9 and 6.2 g (45.1 mmol) of K2CO3 in acetone (67.0 mL), 3.46 mL (36.5 mmol) of 
dimethyl sulfate was added.  The mixture was stirred at reflux for 4.5 h, and cooled to room 
temperature.  Volatile components were removed under reduced pressure.  The residue was then 
diluted with ethyl acetate (75 mL) and H2O (75 mL); the organic layer was extracted, and the 
aqueous layer was washed with additional ethyl acetate (2 x 75 mL).  The combined organic layers 
were washed with brine (200 mL), dried over MgSO4 and filtered, and the volatile components 
were removed under reduced pressure to yield a white solid.  The solid was purified by 
recrystallization to give 2.9 g (100%) of benzoate 15 as white crystals: Rf  0.45  (hexanes/ethyl 
acetate, 4:1); mp 121-122˚C ; IR (thin film, cm-1) ; 1H NMR (300 MHz, CDCl3) δ 7.23 (s, 2H), 
3.95  (s, 6H), 3.93 (s, 3H); 13C NMR (300 MHz, CDCl3) 166.7, 157.3, 130.4, 106.9, 105.8, 56.9, 
52.7; HRMS (ESI-TOF) m/z calc for C10H11BrO4 273.98, found 273.9829.  
CO2CH3
HO OH
Br  
Methyl 4-bromo-3,5-dihydroxybenzoate (16). To 1.0 g (4.4 mmol) of carboxylic acid 9 in 6.8 mL 
of methanol was added .41 mL (7.6 mmol) of H2SO4 dropwise, and the reaction mixture was 
refluxed for 16 h.  The reaction was quenched by addition of NaHCO3 (1.2 g, 14.8 mmol) and the 
volatile components were removed under reduced pressure.  The residue was diluted with ethyl 
acetate (25 mL) and water (25 mL); the organic layer was extracted, and the aqueous layer was 
washed with additional ethyl acetate (3 x 25 mL).  The organic layers were dried over MgSO4 and 
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filtered, and the volatile components were removed from the filtrate under reduced pressure to give 
1.05 g (99%) of 16 as a white solid: Rf  0.34 (hexanes/ethyl acetate 3:2); mp 225-227 °C; IR (thin 
film, cm-1) 3416, 3329, 1701, 1594, 1421, 1353, 1270, 1233, 1118, 1033, 990, 907, 857, 760, 705; 
1H NMR (300 MHz, MeOD) δ 7.03 (s, 2H), 4.85 (broad s, 2H), 3.85 (s, 3H); 13C NMR (600 MHz, 
MeOD) δ 168.1, 156.7, 131.0, 108.6, 105.1, 52.7; HRMS (EI) m/z calcd for C8H7O4Br 245.9528, 
found 245.9519. 
CO2CH3
HO O
Br
Ot-Bu
O  
Methyl 4-bromo-3-(-2-tert-butoxy-2-oxoethoxy)-5-hydroxybenzoate (18).  In a round-bottom 
flask, 1.0 g (4.2 mmol) of benzoate 16, 0.62 mL (4.2 mmol) of t-butyl bromoacetate, 1.2 g (8.8 
mmol) of K2CO3, and 0.05 g (0.2 mmol) of 18-crown-6 were dissolved in acetone (21.0 mL), and 
the reaction mixture was refluxed for 24 h.  The volatile components were removed under reduced 
pressure, and the residue was diluted with ethyl acetate (50 mL) and water (50 mL); the organic 
layer was extracted, and the aqueous layer was washed with additional ethyl acetate (2 x 50 mL).  
The organic layers were dried over MgSO4 and filtered, and the volatile components were removed 
from the filtrate under reduced pressure to give a crude yellow oil.  The oil was purified by flash 
chromatography (SiO2, hexanes/ethyl acetate, elution gradient 5:1/3:2/0:1) to give 0.49 g (32.4%) 
of 18 as a white solid: Rf  0.44 (hexanes/ethyl acetate 3:2); mp 117-118 °C; IR (thin film, cm-1) 
3393, 2923, 2852, 1724, 1590, 1497, 1438, 1354, 1247, 1158, 1117, 1011, 904, 870, 843, 767; 1H 
NMR (400 MHz, CDCl3) δ 7.24 (s, 1H), 6.92 (s, 1H), 6.41 (s, 1H), 4.57 (s, 2H), 3.81 (s, 3H), 1.18 
(s, 9H); 13C NMR (500 MHz, CDCl3) δ 166.9, 166.0, 154.9, 153.7, 130.6, 110.4, 105.8, 105.2, 
82.9, 66.4, 52.5, 28.0; HRMS (EI) m/z calculated for C14H17BrO6 360.0209, found 360.0205. 
  
45 
 
Benzoate 17 was generated as the major product (48%) en route to benzoate 18.  HRMS (EI) m/z 
calcd for C14H17O6Br 360.0209, found 360.0205. 
TBSO OTBS
Brr
CO2CH3
 
Methyl 4-bromo-3,5-bis((tert-butyldimethylsilyl)oxy)benzoate (23).  To a stirred solution of 0.76 
g (5.1 mmol) tert-butyldimethylsilyl chloride in 2.9 mL of THF, 0.5 g (2.0 mmol) 16 and 0.9 mL 
(6.5 mmol) TEA in THF (7.2 mL) was added and stirred for 15 h at room temperature.  The mixture 
was diluted with Et2O (30  mL) and H2O (30 mL); the organic layer was extracted, and the aqueous 
layer was washed with additional Et2O (3 x 30 mL).  The combined organic layers were dried over 
MgSO4 and filtered, and volatile components removed under reduced pressure to give a crude 
white powder.  The powder was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
20:1) to afford 0.87 g (90.8%) of 23 as a white crystal: Rf   0.81 (hexanes/ethyl acetate, 4:1); mp 
˚C ; IR (thin film, cm-1); 1H NMR (300 MHz, CDCl3) δ 7.16 (s, 2H), 3.89 (s, 3H), 1.05 (s, 18H), 
0.26 (s, 12H); 13C NMR (400 MHz, CDCl3) δ 166.7, 157.3, 130.4, 106.9, 105.8, 56.9, 53.2, 29.3, 
17.1, 4.3; HRMS (ESI-TOF) m/z calcd for C20H35BrO4Si2 476.12, found 476.1398.  
OH
NO2
HO
CO2CH3
 
Methyl 2,6-dihydroxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (24).  In a third-flame 
dried round-bottom flask, 5.35 g (21.36 mmol) of a 1.0 M solution of BBr3 in DCM was added 
dropwise over 30 minutes to a stirred solution of 1.18 g (3.56 mmol) of 14 in DCM (8 mL) at 0 
°C.  The reaction mixture was stirred at 0 °C for 3 hours and gradually warmed to room temperature 
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and stirred for an additional 21 h.  The volatile components were removed under reduced pressure.  
The residue was charged with nitrogen and slowly diluted with MeOH (7 mL).  0.33 mL (6.14 
mmol) of H2SO4 was added dropwise at 0 °C.  The reaction mixture was then heated to reflux for 
20 h.  After cooling to room temperature, the reaction was quenched by addition of NaHCO3 (1.03 
g, 12.3 mmol) and the volatile components were removed under reduced pressure. The residue was 
diluted with ethyl acetate (75 mL) and H2O (75 mL); the organic layer was extracted, and the 
aqueous layer was washed with additional ethyl acetate (2 x 75 mL).  The combined organic layers 
were washed with brine (200 mL), dried over MgSO4 and filtered.  Volatile components were 
removed from the filtrate under reduced pressure to yield a brown oil.  The oil was purified by 
flash column chromatography (SiO2, hexanes/ethyl acetate, elution gradient, 2:1) to give 0.84 g 
(78%) of 24 as a white solid: Rf  0.22 (hexanes/ethyl acetate, 2:1); mp 160-161 °C; IR (thin film, 
cm-1) 3310, 2524, 2219, 2043, 1653, 1451, 1113, 1034; 1H NMR (300 MHz, CDCl3) δ 7.92 (d, J 
= 6 Hz, 1H), 7.49-7.47 (m, 2H), 7.31 (s, 2H), 5.71 (broad s, 2H), 3.92 (s, 3H), 2.31 (s, 3H); 13C 
NMR (400 MHz, CDCl3) δ 154.4, 151.7, 135.53, 134.6, 133.7, 131.9, 127.5, 125.2, 118.6, 109.5, 
53.0, 16.4; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C15H14NO6 304.0821, found 304.0837.      
O OBn
O
NO2
O O
BnO
CO2CH3
BrBr
 
Dibenzyl 2,2’-((3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-3’-nitro-[1,1’-biphenyl]-2,6-
diyl)bis(oxy))diacetate (30).  In an oven-dried round bottom flask, 0.46 g (1.0 mmol) of 13, 0.38 
mL (2.4 mmol) of benzyl bromoacetate, 0.42 g (3.0 mmol) of K2CO3, and 0.10 g (0.40 mmol) of 
18-crown-6 were dissolved in acetone (11.1 mL), and the reaction mixture was refluxed for 24 h.  
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The volatile components were removed from the filtrate under reduced pressure, and the residue 
was diluted with DCM (30 mL) and water (30 mL); the organic layer was extracted, and the 
aqueous layer was washed with additional DCM (3 x 30 mL).  The combined organic layers were 
washed with brine (90 mL), dried over MgSO4 and filtered, and the volatile components were 
removed from the filtrate under reduced pressure to give a crude yellow oil.  The oil was purified 
by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 6:1) to yield 0.60 g (80%) 
of 30 as a light yellow foam: Rf  0.48 (hexanes/ethyl acetate 2:1); 1H NMR (400 MHz, CD2Cl2) δ 
7.82 (d, J = 8 Hz, 1H), 7.43 (d, J = 8 Hz, 1H), 7.36-7.34 (m, 6H), 7.30 – 7.24 (m, 5H), 5.02 (q, J 
= 4 Hz, 4H), 4.22, 4.10 (ABq, JAB = 15 Hz, 4H), 2.30 (s, 3H); 13C NMR (400 MHz, CD2Cl2) δ 
167.2, 166.1, 154.0, 151.3, 140.4, 135.8, 135.5, 134.5, 133.1, 131.0, 129.1, 129.0, 128.9, 127.1, 
125.5, 111.7, 70.0, 67.4, 17.2; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C33H28NO10Br2 
758.01052, found 758.0080. 
O OBn
O
NH2
O O
BnO
CO2CH3
BrBr
 
Dibenzyl 2,2’-((3’-amino-3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-[1, 1’-biphenyl]-2,6-
diyl)bis(oxy))diacetate (31). 0.5 g (0.67 mmol) of 30 were dissolved in ethyl acetate (11 ml) and 
concentrated HCl (0.33 ml).  The solution was cooled to 0 °C and Zn powder (.21 g, 3.3 mmol) 
was added in portions over 20 min with stirring.  The mixture was gradually warmed to room 
temperature and stirred for 15 h.  The reaction mixture was passed through a Celite plug and 
washed with ethyl acetate (5 ml).  The filtrate was washed with saturated NaHCO3 solution (1 x 5 
ml), water (1 x 5 ml), and brine (1 x 10 ml).  The organic layer was dried over anhydrous MgSO4, 
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filtered, and volatile components were removed from the filtrate under reduced pressure to give a 
crude yellow oil.  The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
elution gradient 3:1/2:1) to yield 0.41 g (82%) of 31 as a light yellow foam: Rf  0.21 (hexanes/ethyl 
acetate 2:1); mp 58-59 °C;  1H NMR (400 MHz, CDCl3) δ 7.34-7.30 (m, 5H), 7.28-7.25 (m, 5H), 
6.99 (t, J = 8 Hz, 1H), 6.64 (d, J = 8 Hz, 1H), 6.58 (d, J = 7 Hz, 1H), 5.05 (s, 4H), 4.17, 4.00 (ABq, 
JAB = 15 Hz, 4H), 4.01 (s, 3H), 3.61 (broad s, 2H), 1.90 (s, 3H);  13C NMR (400 MHz, CDCl3) δ 
167.6, 166.4, 153.6, 145.6, 138.7, 135.4, 132.1, 131.6, 128.9, 128.8, 128.7, 126.9, 121.9, 120.9, 
115.9, 111.0, 69.4, 67.0, 53.6, 30.0, 14.8; HRMS (ESI-TOF) m/z: [M+H]+  calcd for C33H30NO8Br2 
728.02395, found 728.02593.  
NH2
O
O
O
 
Benzyl 2-(4-amino-3-methylphenoxy)acetate (34).  In a round bottom flask 32 (0.38 g, 0.50 
mmol) was dissolved in ethyl acetate (10 ml) and concentrated HCl (0.25 ml).  The solution was 
cooled to 0˚C and Zn powder (0.23 g, 3.51 mmol) was added in portions over 20 min with stirring.  
The mixture warmed to room temperature and stirred for 15 h.  The reaction mixture was passed 
through a Celite plug and washed with ethyl acetate (5 ml).  The filtrate was washed with satd. 
NaHCO3 solution (1 x 5 ml), water (2 x 5 ml), and brine (1 x 10 ml).  The organic layer was dried 
over anhydrous MgSO4, filtered, and volatile components removed under reduced pressure to give 
a crude brown oil.  The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
elution gradient 7:1/6:1/3:1) to yield 3.26 g (90.2%) of 34 as a white solid: Rf  0.48 (hexanes/ethyl 
acetate 3:2); mp 68-70 ˚C; IR (thin film, cm-1) 3945, 3688, 3055, 2987, 2685, 2411, 2306, 1760, 
1610, 1582, 1517, 1489, 1440, 1422, 1343, 1265, 1196. 1173, 1097, 958, 896, 839, 739;  1H NMR 
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(300 MHz, CDCl3) 2.11 δ (s, 3H), 3.37 (s, 2H), 4.57 (s, 2H), 5.22 (s, 2H), 7.30-7.40 (m, 5H);  
HRMS (ESI-TOF) m/z calcd for [M+H]+ C16H17NO3 272.1200, found 272.1290. 
O OH
O
NO2
O O
HO
CO2CH3
BrBr
 
2,2’-((3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-3’-nitro-[1,1’-biphenyl]-2,6-
diyl)bis(oxy))diacetic acid (35).    To a nitrogen charged flask, 0.03 g (.04 mmol) of 30 and 0.01 
g (0.04mmol) of PtO2 were added and dried under reduced pressure for 5 minutes and backfilled 
with nitrogen twice.  Under hydrogen atmosphere, ethyl acetate (1 mL) was added and stirred for 
2 hours.  The reaction mixture was passed through a Celite plug and washed with ethyl acetate (3 
ml).  Volatile components removed under reduced pressure to obtain .01 g (39%) of 35 as a glass-
like foam.  Rf  0.1 (9:1 ethyl acetate:MeOH);  IR (thin film, cm-1);  1H NMR (400 MHz, CDCl3) δ 
7.79 (d, J = 8 Hz, 1H) 7.46-3.39 (m, 2H), 7.16 (broad s, 2H), 4.24,4.15 (ABq, J = 16,15 Hz, 4H), 
4.04, (s, 3H), 2.32 (s, 3H); 13C NMR (400 MHz, CDCl3) δ 198.3, 165.1, 151.2, 150.9, 138.7, 136.3, 
133.8, 132.2, 127.9, 124.6, 100.5, 54.0, 29.6, 15.1; HRMS (ESI-TOF) m/z calcd for [M-H]- 
C19H15Br2NO10 575.90, found 575.89710. 
 
Dibenzyl 2,2’-((3,5-dibromo-3’-((tert-butoxycarbonyl)amino)-4-(methoxycarbonyl)-2’-methyl-
[1,1’-biphenyl]-2,6-diyl)bis(oxy))diacetate (36). In a round-bottom flask, 0.20 g (.27 mmol) of 31 
and 0.12 g (.54 mmol) of Boc anhydride were dissolved in THF (5 mL), and the reaction mixture 
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was heated to 60 ˚C for 32 h.  The volatile components were removed under reduced pressure; the 
residue was diluted with DCM (15 mL), washed with 1.0 M HCl (2 x 15 mL) and water (15 mL), 
dried over MgSO4 and filtered, and the volatile components were removed under reduced pressure 
to give a crude light pink solid.  The foam was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient 7:1/6:1/3:1) to yield .2 g (89%) of 36 as an off-white solid: 
Rf  0.49 (hexanes/ethyl acetate 2:1); IR (thin film, cm-1) 3429, 3055, 2975, 2305, 2092, 1643, 1422, 
1265, 896, 745;  1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 8, 1H), 7.37-7.31 (m, 5H), 7.25-7.14 
(m, 5H), 7.17 (t, J = 8 Hz, 1H) 6.89 (d, J = 8 Hz, 1H), 6.31 (broad s, 1H), 5.03 (q, J = 2 Hz, 4H), 
4.13,3.96 (ABq, J = 15 Hz, 4H) 4.01 (s, 3H), 1.98 (s, 3H), 1.54 (s, 9H); 13C NMR (300 MHz, 
CDCl3) δ 167.3, 166.1, 153.5, 153.1, 139.0, 137.5, 135.3, 131.7, 131.5, 128.7, 128.7, 126.8, 126.6, 
125.6, 121.3, 111.2, 80.9, 69.3, 67.06, 53.5, 28.6, 28.6, 15.1; HRMS (ESI-TOF) m/z calcd for 
[M+H]+ C38H37Br2NO10 828.0800, found.828.08016. 
 
Dibenzyl 2,2’-((3,5-dibromo-4-methoxycarbonyl)-2’-methyl-3’-(4-nitrophenylsulfonamido)-
(1,1’-biphenyl-2,6-diyl)bis(oxy))diacetate (39). A solution of 0.05 g (0.23 mmol) nosyl chloride 
in 2.3 mL of DCM was added dropwise over 15 min to a stirred solution of 0.18 g (0.25 mmol) of 
31 and 0.02 mL of pyridine (0.25 mmol) in DCM (3 mL). The resulting mixture was stirred at 
room temperature for 12 h.  A 1.0 M HCl solution (5 mL) was added and the acidified aqueous 
phase was separated and extracted with DCM (3 x 5 mL). The combined organic extracts were 
washed with brine (10 mL), dried over MgSO4, and volatile components removed under reduced 
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pressure to give a yellow oil.  The oil was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate, elution gradient 4:1/3:1) to yield 0.16 g (69%) of 39 as a white solid: Rf  0.43 
(hexanes/ethyl acetate 2:1); IR (thin film, cm-1);  1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 9, 
2H), 7.83 (d, J = 9, 2H), 7.36-7.31 (m, 5H), 7.26-7.23 (m, 5H), 7.13 (t, J = 8 Hz, 1H) 7.06 (d, J = 
7 Hz, 1H), 6.58 (broad s, 1H), 5.04 (s, 4H), 4.10,3.92 (ABq, J = 15 Hz, 4H) 3.99 (s, 3H), 1.69 (s, 
3H);13C NMR (300 MHz, CDCl3) δ 167.2, 166.0, 153.4, 150.5, 145.7, 139.5, 135.2, 134.7, 133.0, 
132.9, 131.1, 129.5, 129.0, 128.7, 128.6, 127.0, 124.7, 111.4, 69.4, 67.3, 15.5, 14.5; HRMS (ESI-
TOF) m/z calcd for [M-H]- C39H32Br2N2O12S 911.0000, found 910.9822. 
 
N
H
FmocCl
O  
(9H-fluoren-9-yl)methyl (2-chloro-2-oxoethyl)carbamate (45). To a solution of 0.030 g (0.1 
mmol) of commercially available Fmoc-gly (44) in DCM (0.5 mL) was added 0.07 ml (1.0 mmol) 
of thionyl chloride (SOCl2) and the reaction mixture was refluxed for 30-45 min.  The solution 
was cooled to room temperature and the volatile components were removed under reduced 
pressure.  The residue was dissolved in minimal DCM followed by hexanes to produce an off-
white precipitate.  The solid was filtered and dried in vacuo to afford 0.025 g (81%) of 45 as an 
off-white solid.  Only an IR spectra was obtained to confirm this highly reactive intermediate: (thin 
film, cm-1) 3315, 3066, 2967, 2947, 1811, 1702, 1540, 1477, 1448, 1395, 1349, 1271, 1182, 1104, 
1087, 1051, 991, 955, 919, 780, 758, 742.’ 
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Dibenzyl 2, 2’-((3’-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N-methylacetamido)-3,5-
dibromo-4-(methoxycarbonyl)-2;-methyl-[1,1’-biphenyl]-2,6-diyl)bis(oxy))diacetate (46).  To 
0.050 g (0.07 mmol) of 12 in 0.62 mL of CHCl3 was added 0.03 g (0.09 mmol) of Fmoc-gly acid 
chloride 45 (generated according to above procedure and used immediately thereafter) in 0.37 mL 
of CHCl3 followed by 0.62 mL of saturated NaHCO3 solution, and the reaction mixture was stirred 
at room temperature for 20 min.  The solution was diluted with DCM (10 mL) and saturated 
NaHCO3 solution (10 mL), the organic layer was extracted, and the aqueous layer was washed 
with DCM (3 × 10 mL). The organics were dried over MgSO4 and filtered, and the volatile 
components were removed from the filtrate under reduced pressure to give a light brown crude oil. 
The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 
5:1/3:1/2:1) to give 0.046 g (67%) of 46 as a white foam: Rf 0.31 (hexanes/ethyl acetate, 1:1); IR 
(thin film, cm-1) 3392, 2926, 2855, 1751, 1722, 1660, 1581, 1421, 1369, 1329, 1299, 1234, 1193, 
1134, 1028, 998, 864, 845, 806, 735; 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 7 Hz, 2H), 7.48 
(d, J = 7 Hz, 2H), 7.32-7.25 (m, 5H), 7.22-7.18 (m, 5H), 7.14-7.06 (m, 7H), 5.49 (broad s, 1H), 
4.94 (s, 4H), 4.23-4.14 (m, 4H), 4.10-4.01 (m, 4H), 3.94 (s, 3H), 3.88 (d, J = 15 Hz, 2H), 3.65, 
3.32 (qd, J = 4, 17 Hz, 2H), 3.08 (s, 3H), 1.95 (s, 3H); 13C NMR (400 MHz, CDCl3) δ 168.6, 166.8, 
165.8, 156.1, 153.1, 144.0, 143.9, 141.3, 141.3, 139.3, 136.2, 135.1, 135.0, 133.6, 131.0, 128.7, 
128.6, 128.5, 128.4, 128.3, 127.7, 127.4, 127.1, 125.2, 120.0, 111.3, 111.0, 69.2, 69.1, 67.0, 66.8, 
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53.4, 47.1, 43.2, 36.3, 15.3; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C51H45N2O11Br2 
1019.13846, found 1019.13665.  
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APPENDIX 
1H, 13C NMR SPECTRA  
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